Cost-effectiveness of ward-based pharmacy care in surgical patients: Protocol of the SUREPILL (Surgery & Pharmacy in Liaison) study

BMC Health Services Research

Volumn 11, Issue , 2011, Pages

  De Boer, Monica ^a   Ramrattan, Maya A ^a   Kiewiet, Jordy Js ^a   Boeker, Eveline B ^a   Gombert Handoko, Kim B ^b   Van Lent Evers, Nicolette Aem ^c   Kuks, Paul F ^a   Dijkgraaf, Marcel Gw ^a   Boermeester, Marja A ^a   Lie A Huen, Loraine ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^c DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG TOXICITY; ECONOMICS; EVALUATION; HOSPITAL DEPARTMENT; HOSPITAL PHARMACY; HUMAN; MULTICENTER STUDY; NETHERLANDS; ORGANIZATION AND MANAGEMENT; RANDOMIZED CONTROLLED TRIAL;

COST-BENEFIT ANALYSIS; DRUG TOXICITY; EVALUATION STUDIES AS TOPIC; HUMANS; NETHERLANDS; PHARMACY SERVICE, HOSPITAL; SURGERY DEPARTMENT, HOSPITAL;

EID: 79952319640     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-11-55     Document Type: Article

References (39)

1. Adverse drug events and medication errors: detection and classification methods. T Morimoto TK Gandhi AC Seger TC Hsieh DW Bates, Qual Saf Health Care 2004 13 306 314 10.1136/qshc.2004.010611 15289635 (Pubitemid 39070900)
2. The risk of adverse drug events and hospital-related morbidity and mortality among older adults with potentially inappropriate medication use. RL Page JM Ruscin, Am J Geriatr Pharmacother 2006 4 297 305 10.1016/j.amjopharm. 2006.12.008 17296535
3. Assessing the economic impact of adverse drug effects. R Rodriguez-Monguio MJ Otero J Rovira, Pharmacoeconomics 2003 21 623 650 10.2165/00019053-200321090-00002 12807365 (Pubitemid 36808215)
4. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. DW Bates N Spell DJ Cullen E Burdick N Laird LA Petersen,, et al. JAMA 1997 277 307 311 10.1001/jama.277.4.307 9002493 (Pubitemid 27045011)
5. The incidence and nature of in-hospital adverse events: a systematic review. EN de Vries MA Ramrattan SM Smorenburg DJ Gouma MA Boermeester, Qual Saf Health Care 2008 17 216 223 10.1136/qshc.2007.023622 18519629
6. Incidence and preventability of adverse drug events in hospitalized adults. DW Bates LL Leape S Petrycki, J Gen Intern Med 1993 8 289 294 10.1007/BF02600138 8320571 (Pubitemid 23177840)
7. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. DW Bates DJ Cullen N Laird LA Petersen SD Small D Servi,, et al. JAMA 1995 274 29 34 10.1001/jama.274.1.29 7791255
8. Relationship between medication errors and adverse drug events. DW Bates DL Boyle MB Vander Vliet J Schneider L Leape, J Gen Intern Med 1995 10 199 205 10.1007/BF02600255 7790981
9. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. DW Bates EB Miller DJ Cullen L Burdick L Williams N Laird,, et al. Arch Intern Med 1999 159 2553 2560 10.1001/archinte.159.21.2553 10573045
10. Computerized surveillance of adverse drug events in hospital patients. DC Classen SL Pestotnik RS Evans JP Burke, JAMA 1991 266 2847 2851 10.1001/jama.266.20.2847 1942452
11. Factors associated with preventability, predictability, and severity of adverse drug reactions. K Gholami G Shalviri, Ann Pharmacother 1999 33 236 240 10.1345/aph.17440 10084421 (Pubitemid 29109688)
12. High rates of adverse drug events in a highly computerized hospital. JR Nebeker JM Hoffman CR Weir CL Bennett JF Hurdle, Arch Intern Med 2005 165 1111 1116 10.1001/archinte.165.10.1111 15911723 (Pubitemid 40720734)
13. The Critical Care Safety Study: The incidence and nature of adverse events and serious medical errors in intensive care. JM Rothschild CP Landrigan JW Cronin R Kaushal SW Lockley E Burdick,, et al. Crit Care Med 2005 33 1694 1700 10.1097/01.CCM.0000171609.91035.BD 16096443 (Pubitemid 41153692)
14. Practical approach to determining costs and frequency of adverse drug events in a health care network. BL Senst LE Achusim RP Genest LA Cosentino CC Ford JA Little,, et al. Am J Health Syst Pharm 2001 58 1126 1132 11449856 (Pubitemid 32552897)
15. Clinical pharmacists and inpatient medical care: a systematic review. PJ Kaboli AB Hoth BJ McClimon JL Schnipper, Arch Intern Med 2006 166 955 964 10.1001/archinte.166.9.955 16682568
16. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. SN Kucukarslan M Peters M Mlynarek DA Nafziger, Arch Intern Med 2003 163 2014 2018 10.1001/archinte.163.17.2014 14504113 (Pubitemid 37151242)
17. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. LL Leape DJ Cullen MD Clapp E Burdick HJ Demonaco JI Erickson,, et al. JAMA 1999 282 267 270 10.1001/jama.282.3.267 10422996 (Pubitemid 29343170)
18. Clinical pharmacy services, pharmacy staffing, and the total cost of care in United States hospitals. CA Bond CL Raehl T Franke, Pharmacotherapy 2000 20 609 621 10.1592/phco.20.7.609.35169 10853615 (Pubitemid 30387676)
19. A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals. MJ Dooley KM Allen CJ Doecke KJ Galbraith GR Taylor J Bright,, et al. Br J Clin Pharmacol 2004 57 513 521 10.1046/j.1365-2125.2003.02029.x 15025751 (Pubitemid 38519658)
20. Implementation and pharmacoeconomic analysis of a clinical staff pharmacist practice model. TW Nesbit KM Shermock MB Bobek DL Capozzi PA Flores MC Leonard,, et al. Am J Health Syst Pharm 2001 58 784 790 11351918 (Pubitemid 32422645)
21. Economic effects of clinical pharmacy interventions: a literature review. De Rijdt L Willems S Simoens, Am J Health Syst Pharm 2008 65 1161 1172 10.2146/ajhp070506 18541687 (Pubitemid 351874860)
22. Methodology and rationale for the measurement of harm with trigger tools. RK Resar JD Rozich D Classen, Qual Saf Health Care 2003 12 Suppl 2 i39 ii45 14645894
23. Detection of adverse events in surgical patients using the Trigger Tool approach. FA Griffin DC Classen, Qual Saf Health Care 2008 17 253 258 10.1136/qshc.2007.025080 18678721
24. Institute for Healthcare Improvement. http://www.ihi.org/ihi
25. Development and Evaluation of the Institute for Healthcare Improvement Global Trigger Tool. DCM Classen RCP Lloyd LP Provost FAR Griffin RM Resar, Journal of Patient Safety 2008 4 169 177 Article 10.1097/PTS.0b013e318183a475
26. Medication safety program reduces adverse drug events in a community hospital. MM Cohen NL Kimmel MK Benage MJ Cox N Sanders D Spence,, et al. Qual Saf Health Care 2005 14 169 174 10.1136/qshc.2004.010942 15933311 (Pubitemid 40834916)
27. Adverse drug event trigger tool: a practical methodology for measuring medication related harm. JD Rozich CR Haraden RK Resar, Qual Saf Health Care 2003 12 194 200 10.1136/qhc.12.3.194 12792009 (Pubitemid 36723946)
28. WHO-UMC causality assessment. http://www.who-umc.org/
29. A method for estimating the probability of adverse drug reactions. CA Naranjo U Busto EM Sellers P Sandor I Ruiz EA Roberts,, et al. Clin Pharmacol Ther 1981 30 239 245 10.1038/clpt.1981.154 7249508 (Pubitemid 12149145)
30. Common Terminology Criteria for Adverse Events. http://www.cancer.gov/
31. National Coordinating Council for Medication Error Reporting and Prevention index. http://www.nccmerp.org/
32. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. L van Roijen ML Essink-Bot MA Koopmanschap G Bonsel FF Rutten, Int J Technol Assess Health Care 1996 12 405 415 10.1017/ S0266462300009764 8840661 (Pubitemid 26295783)
33. Euroqol. http://www.euroqol.org/
34. Documentation of pharmacists' interventions in an emergency department and associated cost avoidance. P Lada G Delgado Jr, Am J Health Syst Pharm 2007 64 63 68 10.2146/ajhp050213 17189582 (Pubitemid 46395710)
35. Pharmaceutical care in medical progressive care patients. MA Smythe PP Shah TL Spiteri RL Lucarotti RL Begle, Ann Pharmacother 1998 32 3 294 299 10.1345/aph.17068 9533058 (Pubitemid 28120345)
36. Manual for cost-studies: methods and unit prices for economic evaluations in health care (in Dutch). JB Oostenbrink CAM Bouwmans MA Koopmanschap FFH Rutten, Dutch Health Care insurance board 2004
37. The friction cost method for measuring indirect costs of disease. MA Koopmanschap FFH Rutten BM van Ineveld L van Roijen, J Health Econ 1995 14 171 189 10.1016/0167-6296(94)00044-5 10154656
38. Causes of prescribing errors in hospital inpatients: a prospective study. B Dean M Schachter C Vincent N Barber, Lancet 2002 359 1373 1378 10.1016/S0140-6736(02)08350-2 11978334 (Pubitemid 34442377)
39. The Hawthorne effect. FC Ulmer, Educ Dir Dent Aux 1976 1 28 1069641